Trevi Therapeutics to Present at Stifel Healthcare Conference
10 November 2020 - 11:30PM
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of Haduvio™ (nalbuphine ER) to treat serious
neurologically mediated conditions, today announced that management
will present a Company overview, as well as host virtual investor
meetings, at the Stifel 2020 Virtual Healthcare Conference on
November 17, 2020.
Presentation Time: 10:00 a.m.
ET
A live webcast of the presentation can be accessed by visiting
‘News & Events’ in the ‘Investors & News’ section on the
Company’s website at www.trevitherapeutics.com. An archived replay
of the webcast will also be available for 30 days on the Company’s
website following the conference.
The Company’s corporate presentation is posted to its website in
the ‘Investors & News’ section under ‘News & Events’.
About Trevi
Therapeutics, Inc.Trevi Therapeutics, Inc. is
a clinical-stage biopharmaceutical company focused on the
development and commercialization of Haduvio to treat serious
neurologically mediated conditions. Trevi is currently developing
Haduvio for the treatment of chronic pruritus, chronic cough in
patients with idiopathic pulmonary fibrosis (IPF) and
levodopa-induced dyskinesia (LID) in patients with Parkinson’s
disease. These conditions share a common pathophysiology that is
mediated through opioid receptors in the central and peripheral
nervous systems. Trevi is currently conducting a Phase 2b/3
clinical trial of Haduvio, referred to as the PRISM trial, in
patients with severe pruritus associated with prurigo
nodularis.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About HADUVIO Haduvio is an oral extended
release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe. The ĸ- and
µ-opioid receptors are known to be critical mediators of itch,
cough and certain movement disorders. Nalbuphine’s mechanism of
action also mitigates the risk of abuse associated with µ-opioid
agonists because it antagonizes, or blocks, µ-opioid receptors.
Nalbuphine is currently the only opioid approved for marketing that
is not classified as a controlled substance in the United States
and most of Europe. Trevi intends to propose Haduvio as the trade
name for the nalbuphine ER investigational product. Haduvio is an
investigational drug product and its safety and efficacy have not
been fully evaluated by any regulatory authority.
Investor ContactChris Seiter, Chief Financial
OfficerTrevi Therapeutics,
Inc.203-304-2499chris.seiter@trevitherapeutics.com
Media
Contact Rosalia
Scampoli914-815-1465rscampoli@marketcompr.com
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2024 to May 2024
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From May 2023 to May 2024